New way found to boost immunity in fight cancer and infections

An international research team led by Université de Montréal medical professor Christopher Rudd, director of research in immunology and cell therapy at Maisonneuve-Rosemont Hospital Research Centre, has identified a key new mechanism that regulates the ability of T-cells of the immune system to react against foreign antigens and cancer. T-cells orchestrate the response of the immune system. This work outlines how a receptor termed LFA-1 on the surface of T-cells mediates adhesion to other cells such as cancer cells.

The work, published in Nature Communications, shows that LFA-1 mediates adhesion or de-adhesion by engaging a novel intracellular pathway in T-cells. International work over the past decade has underscored the importance of the manipulation of the immune system to combat cancers and infections. Manipulation of the new pathway outlined by Rudd and his co-researchers represents a new targeting strategy to promote immune-cell rejection of cancer.

"With this work," said Rudd, "we have found a new way to alter the overall immune response. We now have new tools to increase immune response against cancer and infections. The discovery could prove to be a major asset in the fight against several pathologies via the targeting of a single immune cell component."

"It is clear that Dr. Rudd's discovery represents a breakthrough in our ability to understand the immune system and to use it in the fight against cancer and infections," added Denis-Claude Roy, director of research at Maisonneuve-Rosemont Hospital. "This new mechanism allows us to identify the weaknesses of our present immunological approaches and to develop new weapons that are even more effective."

This research brought together the expertise of the Maisonneuve-Rosemont Hospital Research Centre and the University of Cambridge. The lead author is Dr. Monika Raab of the University of Cambridge and J.W. Goethe University). The work was supported by grants from the Wellcome Trust (London) and the CR-HMR Foundation (Montreal).

Monika Raab, Yuning Lu, Karsten Kohler, Xin Smith, Klaus Strebhardt, Christopher E. Rudd.
LFA-1 activates focal adhesion kinases FAK1 / PYK2 to generate LAT-GRB2-SKAP1 complexes that terminate T-cell conjugate formation.
Nature Communications, 2017 July 12.DOI: 10.1038/ncomms16001.

Most Popular Now

FDA approves Vosevi for Hepatitis C

The U.S. Food and Drug Administration has approved Vosevi to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mil...

Green tea ingredient may ameliorate memory impairm…

A study published online in The FASEB Journal, involving mice, suggests that EGCG (epigallocatechin-3-gallate), the most abundant catechin and biologically active compone...

New way found to boost immunity in fight cancer an…

An international research team led by Université de Montréal medical professor Christopher Rudd, director of research in immunology and cell therapy at Maisonneuve-Rosemo...

Amgen and Array BioPharma announce preclinical lic…

Amgen (NASDAQ:AMGN) and Array BioPharma (NASDAQ:ARRY) today announced a collaboration agreement for the discovery and development of novel drugs for autoimmune disorders...

Merck and Pfizer collaborate with Corning

Merck (NYSE: MRK), Pfizer (NYSE: PFE) and Corning Incorporated (NYSE: GLW) today announced collaborations that have enabled the modernization of pharmaceutical packaging ...

One minute of running per day associated with bett…

A single minute of exercise each day is linked to better bone health in women, new research shows. Scientists from the University of Exeter and the University of Leiceste...

Americans say discussions about clinical trials sh…

An overwhelming majority of Americans (86%) agree that health care professionals should discuss clinical trials with patients diagnosed with a disease as part of their st...

AstraZeneca and Merck establish strategic oncology…

AstraZeneca and Merck & Co., Inc., (Merck; known as MSD outside of the US and Canada) today announced that they have entered a global strategic oncology collaboration to ...

27 Phase III and 8 Phase II Alzheimer's drugs on t…

Twenty-seven Alzheimer's drugs in Phase III clinical trials and eight drugs in Phase II clinical trials may launch in the next five years, according to a revised Alzheime...

Johnson & Johnson announces encouraging first-…

Johnson & Johnson has announced encouraging first-in-human clinical data for an investigational HIV-1 vaccine regimen in development at its Janssen Pharmaceutical Compani...

How physical exercise prevents dementia

Numerous studies have shown that physical exercise seems beneficial in the prevention of cognitive impairment and dementia in old age. Now researchers at Goethe Universit...

New drug may treat and limit progression of Parkin…

Researchers at Binghamton University have developed a new drug that may limit the progression of Parkinson's disease while providing better symptom relief to potentially ...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]